Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV – VIRTUAL PRESENTATION

• Laying out the transformative clinical performance of Padcev-Keyruda combination including event free survival in MIBC
• Addressing the need and opportunity for novel combinations partners to enhance Padcev clinical impact
• Breaking down emerging Padcev combinations in bladder cancer

Speakers:

Hussein Sweiti

Vice President, Oncology Clinical R&D

Pfizer